

1. A hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p 6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity.
2. The immunogenic molecule according to claim 1, wherein the Phl p 6 molecule is N-terminally truncated.
3. The immunogenic molecule according to claim 1, wherein the the Phl p 6 molecule is C-terminally truncated.
4. The immunogenic molecule according to any one of claims 1 to 3 which is produced by recombinant techniques.
5. The immunogenic molecule according to any one of claims 1 to 3 which is produced by peptide synthetic chemistry.
6. A hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6.
7. A method for the hyposensitization of a mammal suffering from IgE mediated allergy against a protein allergen, comprising the step of presenting the immune system of the mammal *in vivo* to an effective amount of an immunogenic molecule according to any one of claims 1 to 5 or of an immunogenic molecule combination according to claim 6.

- ²⁵add
- DE2